MYND Life on Biomarkers: Game Changer On Depression And Potential Cure To Alzheimer
MYND Life Sciences recently announced that they would offer $3 million in convertible debenture units to raise capital to expedite the advances in their diagnostic biomarker division.
MYND Life Sciences (OTCPK:MYNDF) is a neuro-pharmaceutical drug development company that hopes to further the exploration into psychedelic compounds and their uses in medicine. Founded by Dr. Wilfred Jefferies and Dr. Lyle Oberg, MYND has made mental health the subject of their psychedelic research, and the capital raised in this offering will further support numerous clinical trials set to begin in Q4 of this year.
MYND CEO Dr. Lyle Oberg joined The Dales Report to discuss this news and to offer a preview into the trials the life science group is scheduled to begin.
In a previous interview, Dr. Oberg emphasized MYND’s focus on the commercialization of its diagnostic biomarkers, a proprietary technology used to track depression and inflammation in the body.
With this technology, Dr. Oberg believes the team at MYND Life Sciences has revolutionized the way the medical community can identify, diagnose, and ultimately treat depression.
“It’s a game-changer because up until now there has been no objective diagnosis of depression. What you had were a group of symptoms.”
Dr. Oberg argues that MYND’s biomarkers would offer an objective test to better determine “if you are depressed or probabally more importantly relapsing or going into remission. This is critically important because everyone will have a baseline because of this biomarker.”
Dr. Oberg and his partner Dr. Jefferies collaborated to develop the concept of ‘biomarkers’. “Basically, if you have an organic cause to something, and we’re suggesting that neuroinflammation is the cause of major depressive disorder. So if you have a physical cause, you can do a biomark that signals when that cause is there, when neuroinflammation is there.”
The current studies are focused on identifying this neuroinflammation and its connection to depression, but Dr. Oberg added that MYND believes the biomarkers can be impactful with PTSD and other mental disorders like schizophrenia.
We are in the midst of a psychedelic renaissance, and the perception of psychedelic therapeutics and their use in the medical community has changed drastically over the past 12 months alone.
A new school of bioscience firms is relying on psychoactive compounds to disprove traditional medical concepts, and investors are lining up as clinical trials continue to side with this new-age approach to mental health.
Psychedelic stocks are slowly making their way into the US exchanges, further supporting the validity and potential that lies in this age-old, yet relatively new industry.
“It’s been absolutely amazing what’s happened over the past year… You are seeing a lot more awareness of this as a medication and a medical treatment than you did even a year ago.”
Dr. Oberg and Dales dive further into biomarkers and the potential they could hold in the fight to cure everything from depression to Alzheimer’s. Interestingly enough, Oberg reveals that MYND has patented a product shown to aid in the remission of Alzheimer’s disease.
This particular patent introduces a novel approach to treating the disease by dissolving the amyloid plaques, actually leading to remission of Alzheimer’s.
Biomarkers, in theory, could be used to direct any condition that is caused by or leads to biological changes in the body, seemingly changing the timetables needed to preventatively diagnose and treat mental illnesses.
“If you can diagnose something early before the complications set in, and you could actually treat it early… imagine the difference that could make.”
‘Cutting edge’ is what it’s going to take to treat and ultimately cure mental illnesses, and the studies being conducted by the revolutionary brain trust at MYND are paving the way for an entire industry on the cusp of changing medicine as we know it.
